Status:
RECRUITING
En Bloc Bladder Tumor Resection: Prospective Randomized Study
Lead Sponsor:
Fundacio Puigvert
Collaborating Sponsors:
KARL STORZ Endoscopy-America, Inc.
Conditions:
Urothelial Carcinoma Bladder
Bladder Cancer
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
INTRODUCTION Bladder tumor is the second most common neoplasm in the genitourinary tract. Most cases of ex novo diagnosis of bladder cancers are present as non-invasive muscle tumors, which are treata...
Eligibility Criteria
Inclusion
- Unifocal primary or recurrent bladder cancer with size less or equal than 3 cm
- Multifocal primary or recurrent bladder cancer less or equal than 3 lesions and with size less or equal than 3 cm
Exclusion
- Evidence of \> 3 tumors or \> 3 cm
- Computed tomography/cystoscopy suspect of muscle-invasive bladder cancer (cT2 or higher)
- Computed tomography/magnetic resonance evidence of distant metastases
Key Trial Info
Start Date :
April 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2026
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT04712201
Start Date
April 1 2018
End Date
April 1 2026
Last Update
January 15 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fundacio Puigvert
Barcelona, Spain, 08025